Saurav Kumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Saurav Kumar has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Jonathan A. Cooper
Fred Hutch Cancer Center
4 shared publications - Behnam Nabet
Human Biology Division, Fred Hutchinson Cancer Center, Seattle, USA
3 shared publications - David Baker
Institute for Protein Design, University of Washington, Seattle, WA, USA
3 shared publications - Mia S. Donald Paladino
Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, 98109, USA
3 shared publications - Xinru Wang
Department of Biochemistry, University of Washington, Seattle, USA
3 shared publications - Adam Nguyen
Division of Basic Sciences Fred Hutchinson Cancer Center Seattle WA USA
2 shared publications
Latest Publications
- Open Access
De novo design of selective kinase modulators
Protein kinases are critical regulators of cellular signaling, but precise modulation of their activity remains challenging due to their high structural conservation. Here, we present de novo designed genetically encoded miniproteins capable of activating or inhibiting focal adhesion kinase (FAK) by directly targeting the kinase domain itself. Among 96 binders designed to stabilize distinct conformational states of FAK, 33 modulated kinase activity. Biochemical characterization of the four most potent modulators revealed that two designs inhibit FAK with low-nanomolar IC50 values while the remaining two potentiated FAK activity by more than two-fold. When expressed in cells, the modulators preserved the same inhibitory and activating effects observed in vitro, establishing that designed conformational binders can directly tune FAK signaling in living cells. Taking advantage of the high similarity between kinases, we redesigned the FAK inhibitors to inhibit Src kinase. Our approach establishes a versatile platform for selective and genetically encoded kinase control as a way to rewire cell signaling and as a starting point for the discovery of novel modulatory sites of kinases.
Open AccessDe novo design of selective kinase modulators
Protein kinases are critical regulators of cellular signaling, but precise modulation of their activity remains challenging due to their high structural conservation. Here, we present de novo designed genetically encoded miniproteins capable of activating or inhibiting focal adhesion kinase (FAK) by directly targeting the kinase domain itself. Among 96 binders designed to stabilize distinct conformational states of FAK, 33 modulated kinase activity. Biochemical characterization of the four most potent modulators revealed that two designs inhibit FAK with low-nanomolar IC50 values while the remaining two potentiated FAK activity by more than two-fold. When expressed in cells, the modulators preserved the same inhibitory and activating effects observed in vitro, establishing that designed conformational binders can directly tune FAK signaling in living cells. Taking advantage of the high similarity between kinases, we redesigned the FAK inhibitors to inhibit Src kinase. Our approach establishes a versatile platform for selective and genetically encoded kinase control as a way to rewire cell signaling and as a starting point for the discovery of novel modulatory sites of kinases.
- Open Access
- 18 March 2026
- Published by Royal Society of Chemistry (RSC) in RSC Chemical Biology
- Vol. 7 (4) , 596-614
Development of PROTACs for targeted degradation of oncogenic TRK fusions
JWJ-01-378 recruits cereblon (CRBN) to induce potent and selective degradation of oncogenic TRK fusions, leading to a collapse in signaling and loss of cancer cell viability. Graphic was created using https://biorender.com.
- 18 March 2026
- Published by Royal Society of Chemistry (RSC) in RSC Chemical Biology
- Vol. 7 (4) , 596-614
Open AccessDevelopment of PROTACs for targeted degradation of oncogenic TRK fusions
JWJ-01-378 recruits cereblon (CRBN) to induce potent and selective degradation of oncogenic TRK fusions, leading to a collapse in signaling and loss of cancer cell viability. Graphic was created using https://biorender.com.
- Open Access
Development of PROTACs for targeted degradation of oncogenic TRK fusions
Chromosomal translocations leading to the fusion of tropomyosin receptor kinases (TRK) with diverse partner proteins have been identified as oncogenic drivers in many adult and pediatric cancers. While first-generation TRK kinase inhibitors, such as entrectinib and larotrectinib, have shown positive responses in TRK fusion-positive cancers, resistance mutations against these inhibitors in the kinase domain limit their efficacy. Second-generation inhibitors are in clinical evaluation, highlighting a need for novel therapeutic modalities to achieve durable suppression of the oncogenic activity of TRK fusions. Here, we developed heterobifunctional small molecule degraders (PROTACs) to achieve targeted degradation of TRK fusions. By conjugating entrectinib to thalidomide, we identified JWJ-01-378 as a potent and selective CRBN-recruiting degrader of the TPM3-TRKA fusion. JWJ-01-378 induced TPM3-TRKA degradation through the ubiquitin-proteasome system and proteomics analysis confirmed the acute selectivity of JWJ-01-378 for achieving TPM3-TRKA degradation with minimal off-target effects. While JWJ-01-378 was also able to degrade wild-type TRK, it was unable to degrade TRK inhibitor resistant mutants and ALK fusions. Importantly, TPM3-TRKA degradation by JWJ-01-378 suppressed downstream signaling and reduced cancer cell viability, with improved responses compared to heterobifunctional control compounds that cannot degrade TPM3-TRKA. Together, our study expands the toolbox of compounds for evaluating targeted degradation of TRK fusions in cancer. Graphical AbstractJWJ-01-378 recruits cereblon (CRBN) to induce potent and selective degradation of oncogenic TRK fusions, leading to a collapse in downstream signaling and loss of cancer cell viability. Graphical abstract was created using Biorender.com.
Open AccessDevelopment of PROTACs for targeted degradation of oncogenic TRK fusions
Chromosomal translocations leading to the fusion of tropomyosin receptor kinases (TRK) with diverse partner proteins have been identified as oncogenic drivers in many adult and pediatric cancers. While first-generation TRK kinase inhibitors, such as entrectinib and larotrectinib, have shown positive responses in TRK fusion-positive cancers, resistance mutations against these inhibitors in the kinase domain limit their efficacy. Second-generation inhibitors are in clinical evaluation, highlighting a need for novel therapeutic modalities to achieve durable suppression of the oncogenic activity of TRK fusions. Here, we developed heterobifunctional small molecule degraders (PROTACs) to achieve targeted degradation of TRK fusions. By conjugating entrectinib to thalidomide, we identified JWJ-01-378 as a potent and selective CRBN-recruiting degrader of the TPM3-TRKA fusion. JWJ-01-378 induced TPM3-TRKA degradation through the ubiquitin-proteasome system and proteomics analysis confirmed the acute selectivity of JWJ-01-378 for achieving TPM3-TRKA degradation with minimal off-target effects. While JWJ-01-378 was also able to degrade wild-type TRK, it was unable to degrade TRK inhibitor resistant mutants and ALK fusions. Importantly, TPM3-TRKA degradation by JWJ-01-378 suppressed downstream signaling and reduced cancer cell viability, with improved responses compared to heterobifunctional control compounds that cannot degrade TPM3-TRKA. Together, our study expands the toolbox of compounds for evaluating targeted degradation of TRK fusions in cancer. Graphical AbstractJWJ-01-378 recruits cereblon (CRBN) to induce potent and selective degradation of oncogenic TRK fusions, leading to a collapse in downstream signaling and loss of cancer cell viability. Graphical abstract was created using Biorender.com.
- Open Access
- 9 June 2025
- Published by Wiley in Advanced Materials
- Vol. 37 (34) , e2500872
De Novo Design of Integrin α5β1 Modulating Proteins to Enhance Biomaterial Properties
Integrin α5β1 is crucial for cell attachment and migration in development and tissue regeneration, and α5β1 binding proteins can have considerable utility in regenerative medicine and next‐generation therapeutics. We use computational protein design to create de novo α5β1‐specific modulating miniprotein binders, called NeoNectins, that bind to and stabilize the open state of α5β1. When immobilized onto titanium surfaces and throughout 3D hydrogels, the NeoNectins outperform native fibronectin (FN) and RGD peptides in enhancing cell attachment and spreading, and NeoNectin‐grafted titanium implants outperformed FN‐ and RGD‐grafted implants in animal models in promoting tissue integration and bone growth. NeoNectins should be broadly applicable for tissue engineering and biomedicine.
- 9 June 2025
- Published by Wiley in Advanced Materials
- Vol. 37 (34) , e2500872
Open AccessDe Novo Design of Integrin α5β1 Modulating Proteins to Enhance Biomaterial Properties
Integrin α5β1 is crucial for cell attachment and migration in development and tissue regeneration, and α5β1 binding proteins can have considerable utility in regenerative medicine and next‐generation therapeutics. We use computational protein design to create de novo α5β1‐specific modulating miniprotein binders, called NeoNectins, that bind to and stabilize the open state of α5β1. When immobilized onto titanium surfaces and throughout 3D hydrogels, the NeoNectins outperform native fibronectin (FN) and RGD peptides in enhancing cell attachment and spreading, and NeoNectin‐grafted titanium implants outperformed FN‐ and RGD‐grafted implants in animal models in promoting tissue integration and bone growth. NeoNectins should be broadly applicable for tissue engineering and biomedicine.
- Open Access
De Novo Design of Integrin α5β1 Modulating Proteins for Regenerative Medicine
Integrin α5β1 is crucial for cell attachment and migration in development and tissue regeneration, and α5β1 binding proteins could have considerable utility in regenerative medicine and next-generation therapeutics. We use computational protein design to create de novo α5β1-specific modulating miniprotein binders, called NeoNectins, that bind to and stabilize the open state of α5β1. When immobilized onto titanium surfaces and throughout 3D hydrogels, the NeoNectins outperform native fibronectin and RGD peptide in enhancing cell attachment and spreading, and NeoNectin-coated titanium implants outperformed fibronectin and RGD-coated implants in animal models in promoting tissue integration and bone growth. NeoNectins should be broadly applicable for tissue engineering and biomedicine. One-Sentence Summary A de novo-designed fibronectin substitute, NeoNectin, is specific for integrin α5β1 and can be incorporated into biomaterials for regenerative medicine.
Open AccessDe Novo Design of Integrin α5β1 Modulating Proteins for Regenerative Medicine
Integrin α5β1 is crucial for cell attachment and migration in development and tissue regeneration, and α5β1 binding proteins could have considerable utility in regenerative medicine and next-generation therapeutics. We use computational protein design to create de novo α5β1-specific modulating miniprotein binders, called NeoNectins, that bind to and stabilize the open state of α5β1. When immobilized onto titanium surfaces and throughout 3D hydrogels, the NeoNectins outperform native fibronectin and RGD peptide in enhancing cell attachment and spreading, and NeoNectin-coated titanium implants outperformed fibronectin and RGD-coated implants in animal models in promoting tissue integration and bone growth. NeoNectins should be broadly applicable for tissue engineering and biomedicine. One-Sentence Summary A de novo-designed fibronectin substitute, NeoNectin, is specific for integrin α5β1 and can be incorporated into biomaterials for regenerative medicine.
- Open Access
- 25 July 2023
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 12
Cas phosphorylation regulates focal adhesion assembly
Integrin-mediated cell attachment rapidly induces tyrosine kinase signaling. Despite years of research, the role of this signaling in integrin activation and focal adhesion assembly is unclear. We provide evidence that the Src-family kinase (SFK) substrate Cas (Crk-associated substrate, p130Cas, BCAR1) is phosphorylated and associated with its Crk/CrkL effectors in clusters that are precursors of focal adhesions. The initial phospho-Cas clusters contain integrin β1 in its inactive, bent closed, conformation. Later, phospho-Cas and total Cas levels decrease as integrin β1 is activated and core focal adhesion proteins including vinculin, talin, kindlin, and paxillin are recruited. Cas is required for cell spreading and focal adhesion assembly in epithelial and fibroblast cells on collagen and fibronectin. Cas cluster formation requires Cas, Crk/CrkL, SFKs, and Rac1 but not vinculin. Rac1 provides positive feedback onto Cas through reactive oxygen, opposed by negative feedback from the ubiquitin proteasome system. The results suggest a two-step model for focal adhesion assembly in which clusters of phospho-Cas, effectors and inactive integrin β1 grow through positive feedback prior to integrin activation and recruitment of core focal adhesion proteins.
- 25 July 2023
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 12
Open AccessCas phosphorylation regulates focal adhesion assembly
Integrin-mediated cell attachment rapidly induces tyrosine kinase signaling. Despite years of research, the role of this signaling in integrin activation and focal adhesion assembly is unclear. We provide evidence that the Src-family kinase (SFK) substrate Cas (Crk-associated substrate, p130Cas, BCAR1) is phosphorylated and associated with its Crk/CrkL effectors in clusters that are precursors of focal adhesions. The initial phospho-Cas clusters contain integrin β1 in its inactive, bent closed, conformation. Later, phospho-Cas and total Cas levels decrease as integrin β1 is activated and core focal adhesion proteins including vinculin, talin, kindlin, and paxillin are recruited. Cas is required for cell spreading and focal adhesion assembly in epithelial and fibroblast cells on collagen and fibronectin. Cas cluster formation requires Cas, Crk/CrkL, SFKs, and Rac1 but not vinculin. Rac1 provides positive feedback onto Cas through reactive oxygen, opposed by negative feedback from the ubiquitin proteasome system. The results suggest a two-step model for focal adhesion assembly in which clusters of phospho-Cas, effectors and inactive integrin β1 grow through positive feedback prior to integrin activation and recruitment of core focal adhesion proteins.
- Open Access
Cas phosphorylation regulates focal adhesion assembly
Integrin-mediated cell attachment rapidly induces tyrosine kinase signaling. Despite years of research, the role of this signaling in integrin activation and focal adhesion assembly is unclear. We provide evidence that the Src-family kinase (SFK) substrate Cas (Crk-associated substrate, p130Cas, BCAR1) is phosphorylated, and associated with its effectors, Crk/CrkL, in clusters that are precursors of focal adhesions. The initial phospho-Cas clusters contain integrin β1 in its inactive, bent closed, conformation. Later, phospho-Cas and total Cas levels decrease as integrin β1 is activated and core focal adhesion proteins including vinculin, talin, kindlin and paxillin are recruited. Cas is required for cell spreading and focal adhesion assembly in epithelial and fibroblast cells on collagen and fibronectin. Cas cluster formation requires Cas, Crk/CrkL, SFKs and Rac1 but not vinculin. Rac1 provides positive feedback onto Cas through reactive oxygen, opposed by negative feedback from the ubiquitin proteasome system. The results suggest a two-step model for focal adhesion assembly in which clusters of phospho-Cas, effectors and inactive integrin β1 grow through positive feedback prior to integrin activation and recruitment of core focal adhesion proteins.
Open AccessCas phosphorylation regulates focal adhesion assembly
Integrin-mediated cell attachment rapidly induces tyrosine kinase signaling. Despite years of research, the role of this signaling in integrin activation and focal adhesion assembly is unclear. We provide evidence that the Src-family kinase (SFK) substrate Cas (Crk-associated substrate, p130Cas, BCAR1) is phosphorylated, and associated with its effectors, Crk/CrkL, in clusters that are precursors of focal adhesions. The initial phospho-Cas clusters contain integrin β1 in its inactive, bent closed, conformation. Later, phospho-Cas and total Cas levels decrease as integrin β1 is activated and core focal adhesion proteins including vinculin, talin, kindlin and paxillin are recruited. Cas is required for cell spreading and focal adhesion assembly in epithelial and fibroblast cells on collagen and fibronectin. Cas cluster formation requires Cas, Crk/CrkL, SFKs and Rac1 but not vinculin. Rac1 provides positive feedback onto Cas through reactive oxygen, opposed by negative feedback from the ubiquitin proteasome system. The results suggest a two-step model for focal adhesion assembly in which clusters of phospho-Cas, effectors and inactive integrin β1 grow through positive feedback prior to integrin activation and recruitment of core focal adhesion proteins.
- 28 July 2021
- Published by Springer Nature
- p. 17-50
Metabolic Reprogramming and the Control of Anoikis Resistance in Cancer
- 28 July 2021
- Published by Springer Nature
- p. 17-50
Metabolic Reprogramming and the Control of Anoikis Resistance in Cancer
- Open Access
Feedback loop involving AMPK, ERK and TFEB generates non-genetic heterogeneity in matrix-deprived cancer cells and regulates survival
Cancer cells metastasize by evading apoptosis induced due to the detachment from the extracellular matrix. Deciphering the adaptive strategies employed by cancer cells in matrix-deprived condition can help design novel therapeutic strategies to tackle metastasis. Here, we provide evidence for non-genetic heterogeneity in matrix-detached cells enabled by feedback loop among AMPK, ERK and TFEB that determines autophagy maturation and cell survival. The subpopulation of matrix-detached cells with pAMPK low /pERK high /TFEB low state show autophagy maturation arrest and elevated cell death. Conversely, pAMPK high /pERK low / TFEB high cells show high autophagy maturation and better cell survival. We show that AMPK inhibits ERK activity in suspension; ERK negatively regulates TFEB which promotes autophagy maturation and re-enforces AMPK. Inhibition of ERK promotes autophagy maturation, cell survival and metastasis in vivo , while AMPK inhibition (and TFEB depletion) renders the population homogeneous by depleting the pAMPK high /pERK low /TFEB high subpopulation, driving detachment-induced death. Such non-genetic heterogeneity is further deciphered by mathematical modelling and RNA-sequencing data of circulating tumor cells (CTCs) isolated from breast cancer patients. Altogether, our work unravels a contextual feedback loop involving two kinases and a transcription factor that helps a subpopulation to evade cell death in matrix-deprived condition. Disrupting such feedback loops may offer improved therapeutic efficacy and a novel approach to constrain metastasis. Significance of the Study: Attachment to the extracellular matrix is pivotal for the growth and survival of normal epithelial cells. In contrast, cancer cells acquest the ability to survive matrix-deprivation and cause cancer spread, or metastasis, which is a leading cause of cancer-related deaths. Non-genetic heterogeneity within cancer cell populations is increasingly being recognized as a major cause of treatment failure. However, the implications of such heterogeneity in the survival of matrix-detached cancer cells remain poorly understood. In this study, we demonstrate feedback loops involving kinases and transcription factor to maintain non-genetic heterogeneous population, where population harbouring pAMPK high /pERK low /TFEB high status shows survival advantage. Targeting such feedback loops that generate non-genetic heterogeneity can open newer therapeutic means to restrict cancer spread.
Open AccessFeedback loop involving AMPK, ERK and TFEB generates non-genetic heterogeneity in matrix-deprived cancer cells and regulates survival
Cancer cells metastasize by evading apoptosis induced due to the detachment from the extracellular matrix. Deciphering the adaptive strategies employed by cancer cells in matrix-deprived condition can help design novel therapeutic strategies to tackle metastasis. Here, we provide evidence for non-genetic heterogeneity in matrix-detached cells enabled by feedback loop among AMPK, ERK and TFEB that determines autophagy maturation and cell survival. The subpopulation of matrix-detached cells with pAMPK low /pERK high /TFEB low state show autophagy maturation arrest and elevated cell death. Conversely, pAMPK high /pERK low / TFEB high cells show high autophagy maturation and better cell survival. We show that AMPK inhibits ERK activity in suspension; ERK negatively regulates TFEB which promotes autophagy maturation and re-enforces AMPK. Inhibition of ERK promotes autophagy maturation, cell survival and metastasis in vivo , while AMPK inhibition (and TFEB depletion) renders the population homogeneous by depleting the pAMPK high /pERK low /TFEB high subpopulation, driving detachment-induced death. Such non-genetic heterogeneity is further deciphered by mathematical modelling and RNA-sequencing data of circulating tumor cells (CTCs) isolated from breast cancer patients. Altogether, our work unravels a contextual feedback loop involving two kinases and a transcription factor that helps a subpopulation to evade cell death in matrix-deprived condition. Disrupting such feedback loops may offer improved therapeutic efficacy and a novel approach to constrain metastasis. Significance of the Study: Attachment to the extracellular matrix is pivotal for the growth and survival of normal epithelial cells. In contrast, cancer cells acquest the ability to survive matrix-deprivation and cause cancer spread, or metastasis, which is a leading cause of cancer-related deaths. Non-genetic heterogeneity within cancer cell populations is increasingly being recognized as a major cause of treatment failure. However, the implications of such heterogeneity in the survival of matrix-detached cancer cells remain poorly understood. In this study, we demonstrate feedback loops involving kinases and transcription factor to maintain non-genetic heterogeneous population, where population harbouring pAMPK high /pERK low /TFEB high status shows survival advantage. Targeting such feedback loops that generate non-genetic heterogeneity can open newer therapeutic means to restrict cancer spread.